Regen BioPharma Discusses Potential Impact of HemaXellerate on Chemotherapy Treament Market
SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight...
immunotherapy
Invitation to the presentation of ALK’s first six months (Q2) 2025 results on Thursday, 21 August 2025
ALK (ALKB.DC / OMX: ALK B) will publish its results for the first six months of 2025 in the morning...
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy
BOSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company...
Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar
Webinar to Review Results from Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Allocetra™ in Patients with Moderate to Severe Knee Osteoarthritis...
24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025
Breakthrough Epigenetic Modulator LB-100 Targets Ovarian Clear Cell Carcinoma, Advanced Soft Tissue Sarcoma, and MSS Metastatic Colon CancerDENVER, Aug. 14,...
Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
Presented positive results from the phase 3 randomized, placebo-controlled clinical trial of CAN-2409 (aglatimagene besadenovec) in localized prostate cancer, during...
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update
NORCROSS, Ga., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target...
Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer
Builds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer.Engineered for precision T-cell activation...
Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer
Builds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer.Engineered for precision T-cell activation...
Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Company Initiates Combination Trial and Strengthens Balance Sheet to Support Continued Clinical ProgressNEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) --...
Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Company Initiates Combination Trial and Strengthens Balance Sheet to Support Continued Clinical ProgressNEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) --...
Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme
First patient dosed with CUE-102 for recurrent glioblastoma multiforme (rGBM) at Dana-Farber Cancer Institute (DFCI) BOSTON, Aug. 13, 2025 (GLOBE...
Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme
First patient dosed with CUE-102 for recurrent glioblastoma multiforme (rGBM) at Dana-Farber Cancer Institute (DFCI) BOSTON, Aug. 13, 2025 (GLOBE...
ModuleMD Ranks No. 585 on the 2025 Inc. 5000 List of America’s Fastest-Growing Private Companies
Innovative Healthcare Technology Company Recognized for Growth, Impact, and Excellence GRAND BLANC, Mich., Aug. 13, 2025 /PRNewswire/ -- Inc., the...
ALK upgrades its full-year revenue outlook
Inside information ALK (ALKB:DC / OMX: ALK B) today announced that the 2025 full-year financial outlook has been upgraded. Revenue...
Flow Cytometry Market worth US$9.85 billion in 2033 with 8.7% CAGR | MarketsandMarkets™
DELRAY BEACH, Fla., Aug. 11, 2025 /PRNewswire/ -- The global Flow Cytometry Market, valued at US$4.87 billion in 2024 stood at US$5.06...
TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with...
TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with...
FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology...
Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update
Mipletamig's 85% frontline AML remission rate and favorable safety profile drive APVO's differentiated CD3 portfolio expansion with APVO455, a Nectin-4...